Bridgepoint is considering options including a sale for its German specialty chemicals maker CABB GmBH, according to four people with knowledge of the situation.
Rothschild is working with the London-based private equity firm as it considers potential exit strategies, said the people, who asked not to be identified because the talks are private. Should Bridgepoint sell CABB, it would probably fetch more than $1 billion, two people said.
Bridgepoint has expanded CABB since its acquisition of the Sulzbach-based monochloroacetic acid maker in 2011. That same year it added KemFine to broaden its client base and offerings of additives used in cosmetics, pharmaceuticals, foods and herbicides.
Officials for Bridgepoint and Rothschild declined to comment and a Cabb representative wasn’t immediately available.
Separately Bridgepoint expects to seek as much as 4 billion euros ($5.6 billion) for its next buyout pool and may start marketing the fund to investors in April, two people briefed on the plans said March 4.
Under Chief Executive Officer Martin Wienkenhover, CABB has targeted Asian markets, entering a joint venture with Karnavati Rasayan of India spanning two plants. The addition of KemFine propelled CABB into one of the global top-three providers of intermediate chemicals for agrochemicals.
Akzo Nobel (AKZA) NA also competes in the market.
To contact the editors responsible for this story: Simon Thiel at email@example.com Robert Valpuesta